Treprostinil and Clinical Outcome in Pulmonary Hypertension and Interstitial Lung Disease: Is All Clear?

Chest. 2023 Jul;164(1):e21. doi: 10.1016/j.chest.2023.04.015.

Authors

Roberto G Carbone¹, Assaf Monselise², Francesco Puppo³

Affiliations

¹ Department of Internal Medicine, University of Genoa, Genoa, Italy. Electronic address: magister1@mail.com.
² Clalit Health Services, Tel Aviv, Israel.
³ Department of Internal Medicine, University of Genoa, Genoa, Italy.

PMID: 37423704
DOI: 10.1016/j.chest.2023.04.015

No abstract available

Publication types

Letter
Comment

MeSH terms

Antihypertensive Agents / therapeutic use
Epoprostenol / therapeutic use
Humans
Hypertension, Pulmonary* / drug therapy
Lung Diseases, Interstitial* / complications
Lung Diseases, Interstitial* / drug therapy
Naphazoline
Treatment Outcome

Substances

treprostinil
Naphazoline
Epoprostenol
Antihypertensive Agents